Protagonist Therapeutics Inc
PTGX50.690USD
+0.480+0.96%
Handelsschluss 07/02, 16:00（ET）Kurse um 15 Minuten verzögert
3.14BMarktkapitalisierung
10.01KGV TTM
mehr Informationen über Protagonist Therapeutics Inc Unternehmen
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Unternehmensinformationen
BörsenkürzelPTGX
Name des UnternehmensProtagonist Therapeutics Inc
IPO-datumAug 11, 2016
Gegründet am2006
CEODr. Dinesh V. Patel, Ph.D.
Anzahl der mitarbeiter126
WertpapierartOrdinary Share
GeschäftsjahresendeAug 11
Addresse7707 Gateway Blvd Ste 140
StadtNEWARK
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94560-1160
Telefon15104740170
Websitehttps://www.protagonist-inc.com/
BörsenkürzelPTGX
IPO-datumAug 11, 2016
Gegründet am2006
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
357.08K
-0.38%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
357.08K
-0.38%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.87%
Farallon Capital Management, L.L.C.
9.85%
RTW Investments L.P.
9.23%
The Vanguard Group, Inc.
6.88%
Deep Track Capital LP
5.24%
Other
54.92%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.87%
Farallon Capital Management, L.L.C.
9.85%
RTW Investments L.P.
9.23%
The Vanguard Group, Inc.
6.88%
Deep Track Capital LP
5.24%
Other
54.92%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
33.20%
Investment Advisor
33.04%
Hedge Fund
30.09%
Research Firm
4.41%
Venture Capital
4.17%
Private Equity
1.86%
Individual Investor
1.10%
Pension Fund
1.03%
Bank and Trust
0.35%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
522
67.76M
109.32%
-9.35M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
2023Q1
397
55.80M
108.46%
-12.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
8.60M
13.87%
-162.95K
-1.86%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.11M
9.85%
+177.00K
+2.98%
Mar 31, 2025
RTW Investments L.P.
5.72M
9.23%
+220.87K
+4.02%
Mar 31, 2025
The Vanguard Group, Inc.
4.27M
6.88%
+57.18K
+1.36%
Mar 31, 2025
Deep Track Capital LP
3.25M
5.24%
+250.00K
+8.33%
Apr 03, 2025
BVF Partners L.P.
3.21M
5.18%
+636.03K
+24.70%
Jun 09, 2025
State Street Global Advisors (US)
2.71M
4.37%
-624.44K
-18.75%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.95%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.42M
2.3%
+46.50K
+3.38%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.27M
2.06%
-71.66K
-5.33%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 23 hours ago
Aktualisiert: 23 hours ago
Name
Anteil
Invesco Biotechnology & Genome ETF
3.93%
Invesco Dorsey Wright Healthcare Momentum ETF
3.07%
ALPS Medical Breakthroughs ETF
2.64%
Invesco S&P SmallCap Health Care ETF
2.02%
Invesco S&P SmallCap 600 Pure Growth ETF
1.86%
ETC 6 Meridian Small Cap Equity ETF
1.43%
Virtus LifeSci Biotech Clinical Trials ETF
1.35%
Inspire Fidelis Multi Factor ETF
0.94%
Invesco S&P SmallCap Quality ETF
0.91%
Cambria Value and Momentum ETF
0.84%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil3.93%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil3.07%
ALPS Medical Breakthroughs ETF
Anteil2.64%
Invesco S&P SmallCap Health Care ETF
Anteil2.02%
Invesco S&P SmallCap 600 Pure Growth ETF
Anteil1.86%
ETC 6 Meridian Small Cap Equity ETF
Anteil1.43%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.35%
Inspire Fidelis Multi Factor ETF
Anteil0.94%
Invesco S&P SmallCap Quality ETF
Anteil0.91%
Cambria Value and Momentum ETF
Anteil0.84%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
